Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹716 Cr.
Stock P/E
26.2
P/B
5.8
Current Price
₹193.1
Book Value
₹ 33.3
Face Value
10
52W High
₹226.5
52W Low
₹ 96
Dividend Yield
—

Kronox Lab Sciences Overview

Business

Kronox Lab Sciences Ltd. is an Indian manufacturer of high-purity specialty fine chemicals for various end-user industries. The company produces a wide range of chemicals, including high-purity inorganic salts, metal salts, phosphorus derivatives, sulfur derivatives, and other specialty compounds. Its products are primarily used in applications such as pharmaceuticals (APIs and excipients), agrochemicals, nutraceuticals, animal nutrition, and scientific research & development. The core business model involves developing and manufacturing these niche chemicals, often with specific purity requirements, and supplying them to B2B customers globally. It makes money by selling these specialized chemical products, leveraging its R&D capabilities, manufacturing processes, and quality control standards.

Revenue Mix

While Kronox Lab Sciences Ltd. does not explicitly report revenue by distinct operational segments in a traditional sense, its product portfolio can be broadly categorized by application and chemical type.

High Purity Inorganic Salts & Metal Salts: Used extensively in pharmaceuticals, agrochemicals, and other industrial applications.

Phosphorus & Sulfur Derivatives: Specialized chemicals for various industrial processes and formulations.

Specialty Fine Chemicals: A broader category catering to specific customer requirements, including chemicals for nutraceuticals, animal nutrition, and R&D.

Its revenue mix is diversified across these product types and caters to both domestic and international markets, with exports forming a significant portion of its sales.

Industry

Kronox Lab Sciences operates in the Indian specialty chemicals industry, which is characterized by a fragmented structure with numerous domestic and international players. The industry benefits from increasing demand from various end-user sectors like pharmaceuticals, agrochemicals, and personal care. Kronox positions itself as a manufacturer of high-purity and niche fine chemicals, often serving specific quality requirements of its customers. It competes with other specialty chemical manufacturers in India and abroad, differentiating itself through product quality, customization capabilities, and adherence to international standards. Its focus on purity and critical applications helps it carve a specific niche within the broader chemicals sector.

MOAT

Kronox Lab Sciences possesses several potential competitive advantages:

Product Quality & Purity: Its focus on manufacturing high-purity chemicals, often meeting pharmacopoeial standards (IP, BP, USP, EP), establishes a reputation for quality, which is crucial for critical applications in pharma and other industries.

R&D and Customization: The ability to develop and customize specific chemical compounds to meet precise customer specifications, supported by in-house R&D, creates stickiness with clients.

Regulatory Compliance: Adherence to stringent quality control and regulatory requirements (e.g., cGMP for pharma-grade products) creates a barrier to entry for new competitors and ensures customer trust.

Diversified Product Portfolio & End-Use Industries: Supplying to multiple industries (pharma, agrochem, nutrition, R&D) reduces dependence on any single sector and provides stability.

Growth Drivers

Increasing Demand from End-User Industries: Growing pharmaceutical, agrochemical, and nutraceutical sectors globally will drive demand for high-purity specialty chemicals.

Expansion of Product Portfolio: Development and introduction of new specialty chemicals and advanced intermediates can open new markets and customer segments.

Export Market Growth: Expanding its global footprint and increasing exports to new geographies can significantly contribute to revenue growth.

"China Plus One" Strategy: Global supply chain diversification away from China could lead to increased outsourcing opportunities for Indian specialty chemical manufacturers like Kronox.

R&D Focus: Continuous investment in R&D to develop innovative products and improve processes can enhance competitiveness and market share.

Risks

Raw Material Price Volatility: Fluctuations in the prices of key raw materials can impact profit margins, as it may not always be feasible to pass on increased costs to customers.

Intense Competition: The specialty chemicals market is competitive, with both domestic and international players, which can put pressure on pricing and market share.

Regulatory Changes: Stricter environmental, health, and safety regulations, particularly in the chemicals and pharmaceutical sectors, could increase compliance costs or affect operations.

Dependence on Key Customers/Sectors: While diversified, over-reliance on a few large customers or a significant downturn in a key end-user industry could impact sales.

Foreign Exchange Fluctuations: Being an exporter and importer, adverse movements in foreign currency exchange rates can impact profitability.

Management & Ownership

Kronox Lab Sciences Ltd. is promoted by key individuals who have been instrumental in the company's establishment and growth. The promoters typically hold a significant stake, aligning their interests with the company's long-term performance. Management quality is generally assessed by their experience in the chemical industry, strategic vision, and ability to navigate market challenges and opportunities. Specific details on individual management performance would require deeper scrutiny of their track record, corporate governance practices, and stakeholder communication.

Outlook

Kronox Lab Sciences is positioned in a growing segment of the specialty chemicals market, driven by increasing demand from diverse end-user industries. Its focus on high-purity products and adherence to quality standards provides a solid foundation for continued business. The company's ability to innovate and expand its product portfolio, coupled with potential benefits from global supply chain realignments, presents growth opportunities. However, the business faces inherent risks from raw material price volatility, intense competition, and evolving regulatory landscapes. Its sustained success will depend on effective cost management, continuous R&D investment, and strategic market expansion while diligently managing operational and financial risks.

Kronox Lab Sciences Share Price

Live · BSE / NSE · Inception: 2008
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Kronox Lab Sciences Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 22 25 25 24 26 24 26 25 26 28
Other Income 1 0 0 1 1 1 1 1 2 1
Total Income 23 26 25 25 27 25 27 26 28 30
Total Expenditure 14 17 16 16 18 16 17 17 17 19
Operating Profit 9 9 9 9 9 9 10 9 12 10
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 1 1 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 8 8 9 9 8 8 9 9 11 10
Provision for Tax 3 2 2 2 2 2 3 2 3 3
Profit After Tax 6 6 6 7 6 6 7 7 8 7
Adjustments 0 0 0 0 -0 0 0 0 0 0
Profit After Adjustments 6 6 6 7 6 6 7 7 8 7
Adjusted Earnings Per Share 1.6 1.7 1.7 1.8 1.7 1.7 1.8 1.8 2.2 2

Kronox Lab Sciences Profit & Loss

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 62 82 96 90 100 101 105
Other Income 1 1 2 2 3 5 5
Total Income 63 83 97 91 103 106 111
Total Expenditure 48 63 74 62 67 67 70
Operating Profit 16 21 24 30 36 39 41
Interest 0 0 0 0 0 0 0
Depreciation 2 2 1 1 1 2 2
Exceptional Income / Expenses 0 0 0 0 0 0 0
Profit Before Tax 13 18 22 29 34 37 39
Provision for Tax 3 5 6 7 9 10 11
Profit After Tax 10 14 16 21 25 28 29
Adjustments 0 0 0 0 0 0 0
Profit After Adjustments 10 14 16 21 25 28 29
Adjusted Earnings Per Share 2.5 3.5 4.4 5.8 6.9 7.5 7.8

Kronox Lab Sciences Balance Sheet

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 27 40 45 66 90 116
Minority's Interest 0 0 0 0 0 0
Borrowings 0 0 0 0 0 1
Other Non-Current Liabilities 3 2 0 -0 -0 -0
Total Current Liabilities 8 14 9 8 9 10
Total Liabilities 37 56 54 74 98 127
Fixed Assets 9 11 16 26 28 29
Other Non-Current Assets 2 1 4 1 7 20
Total Current Assets 26 44 34 47 63 79
Total Assets 37 56 54 74 98 127

Kronox Lab Sciences Cash Flow

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 1 2 3 2 3 3
Cash Flow from Operating Activities 11 9 20 17 31 24
Cash Flow from Investing Activities -3 -8 -7 -17 -28 -24
Cash Flow from Financing Activities -7 -1 -13 0 -2 -0
Net Cash Inflow / Outflow 1 1 -0 0 0 -0
Closing Cash & Cash Equivalent 2 3 2 3 3 3

Kronox Lab Sciences Ratios

# Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 2.49 3.49 4.42 5.75 6.86 7.45
CEPS(Rs) 3 4.01 4.82 6.1 7.24 8.01
DPS(Rs) 0 0 0 0.5 0.5 0.5
Book NAV/Share(Rs) 6.87 10.34 12.06 17.87 24.28 31.3
Core EBITDA Margin(%) 23.7 23.95 22.72 31.51 33.06 33.86
EBIT Margin(%) 21.78 22.81 23.16 31.84 34.2 36.97
Pre Tax Margin(%) 21.17 22.32 23.06 31.84 34.2 36.85
PAT Margin (%) 15.58 16.57 17.16 23.76 25.42 27.33
Cash Profit Margin (%) 18.74 19.04 18.73 25.19 26.8 29.35
ROA(%) 26.01 29.03 29.73 33.54 29.61 24.53
ROE(%) 36.29 40.58 38.55 38.45 32.56 26.82
ROCE(%) 50.71 55.32 51.63 51.52 43.82 36
Receivable days 90.24 91.52 84.69 73.51 68.37 74.05
Inventory Days 32.11 28.85 31.86 37.42 28.46 26.58
Payable days 69.52 69.59 64.28 56.53 50.41 54.3
PER(x) 0 0 0 0 20.96 13.09
Price/Book(x) 0 0 0 0 5.92 3.12
Dividend Yield(%) 0 0 0 0 0.35 0.51
EV/Net Sales(x) -0.03 -0.02 0.35 0.37 4.96 3.11
EV/Core EBITDA(x) -0.12 -0.09 1.42 1.12 13.94 7.98
Net Sales Growth(%) 0 31.68 16.21 -5.98 11.5 1.02
EBIT Growth(%) 0 37.91 17.99 29.25 19.79 9.18
PAT Growth(%) 0 40.05 20.37 30.17 19.28 8.61
EPS Growth(%) 0 40.05 26.66 30.16 19.28 8.61
Debt/Equity(x) 0 0.02 0 0 0 0.01
Current Ratio(x) 3.3 3.21 3.82 6.07 7.28 7.6
Quick Ratio(x) 2.61 2.66 2.8 4.87 6.55 6.8
Interest Cover(x) 35.61 46.32 237.24 0 0 328.21
Total Debt/Mcap(x) 0 0 0 0 0 0

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +1% +2% +10% —
Operating Profit CAGR +8% +18% +20% —
PAT CAGR +12% +21% +23% —
Share Price CAGR +25% — — —
ROE Average +27% +33% +35% +36%
ROCE Average +36% +44% +48% +48%

Kronox Lab Sciences Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 74.21 %
FII 0.04 %
DII (MF + Insurance) 2.07 %
Public (retail) 23.67 %
Others 0.01 %
# Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 74.2174.2174.2174.2174.2174.2174.2174.2174.21
FII 1.560.550.480.040.030.030.050.080.04
DII 4.342.572.22.21.711.9322.052.07
Public 19.8922.6723.123.5524.0523.8323.7523.6623.67
Others 000000000
Total 100100100100100100100100100

Kronox Lab Sciences Peer Comparison

Chemicals Edit Columns

Kronox Lab Sciences Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Kronox Lab Sciences Pros & Cons

Pros

  • Company has delivered good profit growth of 22% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 33%
  • Company is almost debt free.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend.
  • Debtor days have increased from 50.41 to 54.3days.
  • Stock is trading at 5.8 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp